Transcript Intelligence: Shionogi & Co. Q1 Earnings Guidance
StreetAccount Metrics Recap - Shionogi & Co. Q1 Earnings (¥2898.5000, 0)
ViiV's Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV
ViiV Healthcare announces data to be presented from Phase IIIb VOGUE study of Dovato at AIDS 2026
Apnimed, Inc. files amended S-1; expects to offer 10.0M shares priced in the range of $14-16/sh
Powered by FactSet Research Systems Inc.